SCHEMBL8725909

SCHEMBL8725909

CC(C)S(=O)(=O)Nc1ccc2scc(C3=CCN4CCCCC4CC3)c2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.33
EHMT1 Q9H9B1 1/20 0.33
CCNT1 O60563 2/20 0.32
CDK9 P50750 2/20 0.32
BRD4 O60885 3/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
HTR2A P28223 1/20 0.32
ADRA1B P35368 1/20 0.32
DRD3 P35462 1/20 0.32
HTR2B P41595 1/20 0.32
HTR6 P50406 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
MLNR O43193 1/20 0.31
CYP2D6 P10635 1/20 0.30
BRPF1 P55201 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725946 0.91 MLNR (0.33) EHMT2EHMT1HTR1ADRD2HTR1D
SCHEMBL8723706 0.82 MLNR (0.36) EHMT2EHMT1HRH3MLNR
SCHEMBL8724051 0.81 AKR1C3 (0.38) EHMT2EHMT1HRH3MAPTCYP2D6
SCHEMBL8724068 0.80 KDM4E (0.43) HTR1ATP53MAPTCYP2D6
SCHEMBL8720711 0.78 TP53 (0.44) TP53MAPT
SCHEMBL8725944 0.77 HRH3 (0.34) CDK9BRD4HTR1ADRD2HTR1D
SCHEMBL8725926 0.77 TDP1 (0.41) TP53MAPT
SCHEMBL8724021 0.77 HTR1F (0.40) HTR1AHTR1DHTR1BHRH3TP53
SCHEMBL8720679 0.77 MAPK14 (0.38) HRH3TP53MAPT
SCHEMBL8721911 0.77 KMT2A (0.43) HRH3TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D EHMT2 1113/4885EHMT1 627/4885CCNT1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.